F Dx Advisors, Inc. Vertex Pharmaceuticals Inc Transaction History

F Dx Advisors, Inc.

$367 Million
Q3 2024

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$407.69 - $446.08 $1.1 Million - $1.2 Million	-2,699 Reduced 48.23%	2,897 $1.21 Million
Q4 2023 Feb 12, 2024	SELL	$343.0 - $410.68 $45,619 - $54,620	-133 Reduced 2.32%	5,596 $2.28 Million
Q3 2023 Nov 02, 2023	SELL	$338.18 - $362.46 $1.07 Million - $1.14 Million	-3,153 Reduced 35.5%	5,729 $1.99 Million
Q2 2023 Jul 17, 2023	BUY	$314.42 - $351.91 $532,941 - $596,487	1,695 Added 23.58%	8,882 $3.13 Million
Q4 2022 Feb 09, 2023	SELL	$285.76 - $321.48 $316,336 - $355,878	-1,107 Reduced 13.35%	7,187 $2.08 Million
Q3 2022 Nov 10, 2022	SELL	$273.83 - $305.53 $783,975 - $874,732	-2,863 Reduced 25.66%	8,294 $2.4 Million
Q2 2022 Aug 03, 2022	SELL	$234.96 - $292.55 $548,631 - $683,104	-2,335 Reduced 17.31%	11,157 $3.14 Million
Q1 2022 May 03, 2022	SELL	$221.42 - $260.97 $237,805 - $280,281	-1,074 Reduced 7.37%	13,492 $3.52 Million
Q4 2021 Feb 01, 2022	BUY	$177.01 - $223.45 $786,455 - $992,788	4,443 Added 43.89%	14,566 $3.2 Million
Q3 2021 Oct 08, 2021	BUY	$181.39 - $202.99 $829,133 - $927,867	4,571 Added 82.33%	10,123 $1.84 Million
Q2 2021 Aug 05, 2021	SELL	$187.49 - $221.1 $27,748 - $32,722	-148 Reduced 2.6%	5,552 $1.12 Million
Q1 2021 Apr 14, 2021	BUY	$207.02 - $241.31 $926,414 - $1.08 Million	4,475 Added 365.31%	5,700 $1.23 Million
Q1 2021 Apr 13, 2021	SELL	$207.02 - $241.31 $777,360 - $906,119	-3,755 Reduced 75.4%	1,225 $263,000
Q4 2020 Feb 08, 2021	BUY	$207.01 - $276.09 $167,057 - $222,804	807 Added 19.34%	4,980 $1.18 Million
Q3 2020 Nov 12, 2020	SELL	$255.65 - $303.1 $114,531 - $135,788	-448 Reduced 9.69%	4,173 $1.14 Million
Q2 2020 Jul 22, 2020	BUY	$225.48 - $295.8 $263,360 - $345,494	1,168 Added 33.83%	4,621 $1.34 Million
Q1 2020 May 22, 2020	SELL	$199.77 - $247.81 $131 Million - $163 Million	-657,216 Reduced 99.48%	3,453 $822,000
Q1 2020 May 13, 2020	BUY	$199.77 - $247.81 $131 Million - $163 Million	657,114 Added 18484.22%	660,669 $837,000
Q4 2019 Feb 12, 2020	SELL	$166.71 - $223.91 $72,685 - $97,624	-436 Reduced 10.92%	3,555 $778,000
Q3 2019 Nov 07, 2019	BUY	$166.23 - $187.09 $14,628 - $16,463	88 Added 2.25%	3,991 $676,000
Q2 2019 Jul 19, 2019	BUY	$164.61 - $190.37 $37,037 - $42,833	225 Added 6.12%	3,903 $716,000
Q1 2019 May 14, 2019	SELL	$163.73 - $194.7 $82,028 - $97,544	-501 Reduced 11.99%	3,678 $677,000
Q4 2018 Apr 29, 2019	SELL	$151.91 - $192.21 $138,086 - $174,718	-909 Reduced 17.87%	4,179 $693,000
Q4 2018 Feb 07, 2019	BUY	$151.91 - $192.21 $89,474 - $113,211	589 Added 13.09%	5,088 $843,000
Q3 2018 Nov 13, 2018	SELL	$167.73 - $192.74 $7,212 - $8,287	-43 Reduced 0.95%	4,499 $867,000
Q2 2018 Aug 08, 2018	SELL	$145.72 - $169.96 $105,792 - $123,390	-726 Reduced 13.78%	4,542 $772,000
Q1 2018 May 02, 2018	SELL	$151.6 - $177.13 $112,032 - $130,899	-739 Reduced 12.3%	5,268 $859,000
Q4 2017 Feb 09, 2018	BUY	$137.28 - $155.55 $109,549 - $124,128	798 Added 15.32%	6,007 $900,000
Q3 2017 Nov 03, 2017	BUY	$148.13 - $162.24 $89,618 - $98,155	605 Added 13.14%	5,209 $792,000
Q2 2017 Aug 11, 2017	BUY	N/A	4,604	4,604 $593,000

Others Institutions Holding VRTX

# of Institutions

1,718

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$11.3 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$9.77 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$8.99 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$4.99 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$3.8 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $108B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on F Dx Advisors, Inc. with notifications on news.

Account